Health Care Technology

Forian

Forian released FY2026 Q1 earnings on May 15 (EST), actual revenue USD 6.851 M, actual EPS USD -0.1099

Forian released FY2025 Annual Earnings on March 27 (EST), actual revenue USD 30.26 M (forecast USD 30 M), actual EPS USD -0.0923 (forecast USD -0.05)

Forian released FY2025 Q4 earnings on March 27 (EST), actual revenue USD 7.962 M (forecast USD 7.702 M), actual EPS USD -0.0601 (forecast USD -0.02)

Forian released FY2025 Q3 earnings on November 14 After-Market (EST), actual revenue USD 7.762M (forecast USD 7.264M), actual EPS USD -0.0048 (forecast USD -0.04)

Forian released FY2025 9 Months Earnings on November 14 After-Market EST, with actual revenue of USD 22.29 M and EPS of USD -0.0376

Forian to Release FY2025 Q3 Earnings on November 14 After-Market EST, Forecast Revenue USD 7.264 M, EPS USD -0.04

Forian released FY2025 Semi-Annual Earnings on August 13 After-Market (EST), actual revenue USD 14.53 M, actual EPS USD -0.0299

Forian released FY2025 Q2 earnings on August 13 After-Market EST, actual revenue USD 7.476 M (forecast USD 7.166 M), actual EPS USD 0.0072 (forecast USD -0.04)

Forian to Release FY2025 Q2 Earnings on August 13 After-Market EST, Forecast Revenue USD 7.166 M, EPS USD -0.04

Forian Inc. Reports Q1 2025 Financials

Forian released FY2025 Q1 earnings on May 14 After-Market EST, actual revenue USD 7.056 M (forecast USD 5.365 M), actual EPS USD -0.04 (forecast USD -0.03)

Forian Inc Sees 2025 Full-Year Revenue of $28-30 Million

Forian Expected to Report Q1 2025 EPS of $0.02

Forian to release FY2025 Q1 earnings on May 14 After-Market EST, forecast revenue USD 5.365 M, EPS USD -0.03

Forian released FY2024 Q4 earnings on April 11 After-Market (EST), actual revenue USD 5.812 M (forecast USD 5.369 M), actual EPS USD 0.0064 (forecast USD -0.03)

Forian released FY2024 annual earnings on April 11 After-Market EST, actual revenue USD 20.15 M (forecast USD 19.71 M), actual EPS USD -0.1213 (forecast USD -0.16)

Forian Inc. Delays Submission of 10-K Form Due to Improper Revenue Recognition Found in Audit

Forian Inc expects quarterly revenue of $5.369 million and a loss of $0.03 per share

Forian to Release FY2024 Q4 Earnings on March 27 After-Market EST, Forecast Revenue 5.369 M USD, EPS -0.03 USD

Forian Inc. CEO Max C. Wygod Purchases 12,320 Shares at $2.67 Each

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

FORA

Earnings Watch

Forian | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 6.851 M

Forian Inc. has completed a take-private merger with 2025 Acquisition Company, LLC, acquiring outstanding shares at $2.17 each. Following the merger, Forian will delist from Nasdaq and cease public reporting. The transaction resulted in a board shake-up, with Max Wygod as the sole director. Analysts rate FORA stock as Hold with a $2.10 price target, citing weak financial performance but improved near-term value realization post-merger.

Tip Ranks

Forian Completes Take-Private Merger and Nasdaq Delisting

Fora, a modern travel agency, has been named to TIME's 2026 TIME100 Most Influential Companies list, recognizing its significant impact in the travel industry. The company has transformed the travel landscape by empowering over 15,000 new travel advisors to build successful businesses on its platform. Co-founders Henley Vazquez and Jake Peters emphasize the importance of human expertise enhanced by technology. Fora aims to expand its influence by enabling more entrepreneurs in travel and improving efficiency through technology, while also being recognized as an industry leader in Travel and Tourism.

prnewswire

07:50 ETFora Named One of TIME100 Most Influential Companies 2026

KORE

Halper Sadeh LLC is investigating Leggett & Platt, Select Medical, KORE Group, and Forian for potential violations of federal securities laws and fiduciary duties to shareholders. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders and is encouraging affected shareholders to discuss their rights and options. The investigations focus on the terms of proposed sales and may seek increased consideration or additional disclosures for shareholders.

Select Medical

Leggett & Platt

11:15 ETAre LEG, SEM, KORE, FORA Obtaining Fair Deals for their Shareholders?

Levi & Korsinsky, LLP has initiated an investigation into Forian Inc. (NASDAQ: FORA) regarding potential breaches of fiduciary duty by its Board of Directors related to a merger agreement with a consortium led by Max Wygod. Shareholders, excluding those in the consortium, are expected to receive $2.17 per share in cash. The investigation aims to determine if the Board acted in the best interests of the shareholders. For more information, contact Levi & Korsinsky, LLP.

14:50 ETSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Forian Inc. ("FORA").

GSAT

APLS

Halper Sadeh LLC is investigating Globalstar, Inc. (GSAT), Apellis Pharmaceuticals, Inc. (APLS), and Forian Inc. (FORA) for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders. They are encouraging shareholders to discuss their rights and options regarding the proposed transactions, which may limit competing offers. The firm operates on a contingent fee basis, meaning no upfront legal fees for clients.

Globalstar

Apellis Pharma

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

iShares US Pharma

iShares Biotechnology ETF

VG Health

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Amazon

Biogen

16:15 ETAre GSAT, APLS, FORA Obtaining Fair Deals for their Shareholders?

VerticalScope Holdings Inc. (TSE:FORA) saw its stock price decline by 0.4%, trading between C$2.67 and C$2.79. Analysts have lowered their price targets, with National Bank Financial setting it at C$4.50, Raymond James at C$5.00, and TD Securities at C$3.00. The company reported a quarterly EPS of C($0.22) and revenue of C$20.22 million. Currently, it holds a market cap of C$60.49 million and has a consensus rating of "Hold" with a target price of C$4.83. Investment analysts suggest caution with the stock.

Market Beat

VerticalScope (TSE:FORA)  Shares Down 0.4%   - Here's What Happened

CPER

ICOP

COPX

COPP

Eldorado Gold shareholders have approved the acquisition of Foran Mining, adding a copper gold project to its portfolio. The company also announced a project execution alliance with G Mining Services. This move indicates a shift in Eldorado's project planning and execution strategy, particularly in Canada. While the acquisition aims to diversify revenue through copper exposure, concerns about overpayment and execution risks persist. Investors will closely monitor how Eldorado integrates Foran and manages capital sequencing to enhance cash flow per share.

Forian(FORA.US)